Repository logo
Communities & Collections
All of MSAR
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
New user? Click here to register. Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "El Mahdy, Nihal M."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Item
    Rivastigmine
    (Elsevier, 2021-01) Ezzat, Shahira M; Salem, Mohamed A.; El Mahdy, Nihal M.; Ragab, Mai F.
    Alzheimer's disease (AD) is a neurodegenerative dementing disease characterized by slowly increasing impairment in memory, cognition, speech, and behavioral functions, such as the recognition of objects and people, as a result of neuronal cell death. Acetylcholine (ACh) is a neurotransmitter that is implicated in several processes, including learning and regulation of cognitive functions. To date, there is no cure for AD; all available treatments aim merely to alleviate the symptoms of this condition. This can be achieved by improving neurotransmission by inhibiting the breakdown of ACh, thus improving attention, memory, learning, and cognitive functions. In this chapter, we will provide an overview of rivastigmine, an acetylcholinesterase inhibitor ratified by the Food and Drug Administration to control mild to moderate stages of AD.

October University for Modern Sciences and Arts Established by Dr. Nawal El Degwi in 1996 copyright © 2019-2024

DSpace software copyright © 2002-2025 LYRASIS

  • Privacy policy
  • End User Agreement
  • Send Feedback